Help

The 14th Annual BIO Investor Forum

General Information
Conference Banner: 
Events Banner Image: 
Events Library Thumbnail: 
Conference Start Date: 
January 1, 2014
Conference End Date: 
January 1, 2014
Homepage Center Column Content: 

Download the BIF eBrochure

Download the 2014 Program Schedule

BIO Investor Forum Statistics

  • Over 600 attendees from 21 different countries
  • Over 200 investors in attendance 
  • Over 1400 parterning meetings scheduled, a 51% increase since 2013
  • 56% of attendees were executives in 2014
  • The event hosted 128 private and public company presentations.

Attendees by Type

Conference Sidebar Custom: 

Follow BIO Investor Forum
on Twitter, and join the conversation:#BIF14
Join the official LinkedIn Group




Local Co-Host

Industry Sponsor

 

Supporting Bank Sponsors

Double Helix Sponsors

Helix Sponsor

Conference Sponsors

Media Partners

BIO Investor Forum 
Parc 55 Wyndham, San Francisco
October 20-21, 2015

Sign up to receive the latest updates about this conference as well as other BIO events.

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One PartneringTM meetings.

BIO One-on-One PartneringTM provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads. 

What People are Saying About the BIO Investor Forum

"For us, the BIO Investor Forum is the bellwether of life science investing and business creation. As such, it's the "must go to" meeting on our calendar each year." - Graeme Martin, CEO, Takeda Ventures

“The BIO Investor Forum over the years has proved to be an excellent venue for investors to interact with a high quality group of emerging biotechnology companies and their senior management teams.  The ongoing exposure to the investor community is invaluable to this group of companies as they execute their business strategies, achieve significant clinical catalysts and ultimately look to the capital markets to fund their continued advancement.  Given my experience over the years, I have found this well-orchestrated conference to be a “must-attend” annual event.” - John Chambers, ROTH Capital Partners